You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Zealand Pharma's Zeydovio (glepaglutide) receives positive CHMP opinion for short bowel syndrome treatment

MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion

Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes

Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase

Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system

VaxThera partners with Codagenix for next generation yellow fever vaccine advancement

MaaT Pharma receives negative CHMP trend vote for MaaT013

FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy

FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis

Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02

GSK reports positive Jideytro data supporting potential first-line lung cancer use

Eloxx Pharmaceuticals commences Phase 2b study of exaluren

Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions

US FDA grants orphan drug designation for Lundbeck's asedebart

Renova Pharmaceuticals launches first three US generic products

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026